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1. Introduction
This chapter will focus on the role of innate immunity induction on antiviral responses with
an emphasis on nucleic acids as type-I interferon (IFN) inducers and their use as antiviral
compounds and vaccine adjuvants. A general and up-to-date view of the different mechanisms
operating in the host cell for sensing viral genomes will be given, as well as viral strategies
counteracting this response through immune evasion or specifically targeted antagonism. Our
own recent data describing the ability to induce IFN and mediate protection against viral
infection in vivo of synthetic RNA transcripts enclosing structural domains present in the 5´-
and 3´-terminal regions of the foot-and-mouth disease virus (FMDV) genome will be sum‐
marized and discussed in this context. New vaccine formulations including innate immunity
inducers are being developed for improvement of current vaccines. The potential of exogenous
nucleic acids as modulators of immune response outcomes and vaccine adjuvants will be
reviewed and discussed. A schematic summary of the interrelated topics addressed in this
chapter is shown in Figure 1. Additionally, a glossary of all the acronyms and abbreviations
used in the text and figures is shown in Table 1.
2. Innate immune response against viral infection
The mammalian immune system is composed of the innate and the adaptive arms which work
in combination to battle against a large variety of pathogens such as bacteria, fungi, parasites
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and viruses. Both systems have the molecular task to distinguish “self” from “non-self”
components in the organisms in a sensitive and faithful manner. The innate immune system
is hence the first line of defense against infection by pathogens. The existence of pattern-
recognition receptors (PRRs) expressed in cells of the innate immune system that are capable
to specifically sense pathogen-associated molecular patterns (PAMPs) was first proposed by
Charles Janeway in 1989 [1]. PAMPs are chemical or structural features present in pathogens
but not in host cells acting then as alert signals to the innate immune system of the host. Lipids,
polysaccharides, nucleic acids and CpG DNA are among the basic PAMPs recognized by PRRs.
Their recognition triggers cellular responses aimed to counteract the pathogen and initiate and
promote other responses such as inflammation and adaptive immune responses.
In 1996, the gene/protein Toll, initially described as a transmembrane protein required for
dorsal-ventral polarity in the Drosophila embryo, was found to play also a role in immunity
against fungal infections [2]. One year later, their mammalian orthologs, the Toll-like receptors
(TLRs), were reported to mediate recognition of pathogens by the innate immune system [3].
In 2004, a new and TLR-independent pathway was described for recognition of viral nucleic
acids in the cytoplasm of the infected cells, the retinoic acid-inducible gene-1 (RIG-I) [4]. Four
different families of PRRs have been found to date, including TLRs [5], RIG-I-like receptors
(RLRs), C-type lectin receptors (CLRs) [6] and nucleotide oligomerization domain (NOD)-like
receptors, (NLRs) [7], as well as unidentified proteins that mediate sensing of cytosolic DNA
or retroviral infection [8]. Among them, TLRs, RLRs and NLRs are involved in the recognition
of viral nucleic acids [9]. NOD2, a member of the NLR family, typically involved in antimi‐
crobial immune defenses, and highly expressed in antigen presenting cells (APCs) such as
monocytes, macrophages and dendritic cells (DCs), has been shown to bind viral single-
stranded (ss) RNA [10].
TLRs are a family of type-I transmembrane proteins that traffic between the plasma membrane
and endosomal vesicles, expressed on various immune cells, including dendritic cells, which
recognize a wide range of PAMPs including double-stranded (ds) RNA (TLR3), ssRNA (TLR7
and TLR8) and DNA (TLR9). All TLRs signal as dimmers and share a common architecture of
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Figure 1. Schematic summary of the topics reviewed and discussed in this chapter
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extracellular leucine-rich repeats and intracellular Toll/Interleukin-1 receptor (TIR) domain
(Figure 2). Nucleic acid sensing-TLRs localize in intracellular vesicles, including endoplasmic
reticulum (ER), endosomes, lysosomes and endolysosomes of dendritic cells and other innate
immune cells. Intracellular localization enables TLRs to recognize nucleic acids delivered to
intracellular compartments after the uptake of viruses or infected cells. Unc93b1 is a membrane
protein which anchors TLRs to the ER and regulates their trafficking to the endosomal
compartments. TLR signaling pathway depends on the recruitment of a TIR-domain contain‐
ing adaptor, MyD88, for all TLRs (with the exception of TLR3) and culminates with NF-κB and
MAP kinase activation and induction of inflammatory cytokines (Figure 2). TLR3 uses TRIF
to activate NF-κB and IRF-3 through an alternative pathway and the induction of type-I IFN
and inflammatory cytokines. Activation of the TLR signaling leads to maturation of DCs,
contributing to the induction of adaptive immunity.
The RLRs are a family of ubiquitous cytosolic helicases consisting of the three members: RIG-
I, melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physi‐
ology-2 (LGP2) (Figure 2). RIG-I and MDA5 have tandem caspase activation and recruitment
domains (CARD) followed by a DExD/H box RNA helicase domain and a repressor domain.
LGP2 lacks the N-terminal CARD domains and may function to regulate RIG-I and MDA5 as
a repressor [11]. It has been reported that RIG-I recognizes ssRNA bearing a 5´-ppp and short
dsRNA, while MDA5 senses long dsRNA [12-14]. When the inactive forms of RIG-I or MDA5
bind viral RNA, the helicases undergo a conformational change, multimerization and then,
interaction with the adaptor molecule MAVS (also called IPS1, VISA or CARDIF), localised to
the outer mitochondrial membrane via CARD-CARD interaction. Then, MAVS induces
activation of IRF3/7 resulting in the transcription of type-I IFNs and also activates NF-κB
(Figure 2). It has been recently shown that MAVS resides on peroxisomes also and can induce
antiviral signaling from this organelle acting with mitochondrial MAVS sequentially to create
an antiviral cellular state [15]. Upon viral infection, peroxisomal MAVS induces the rapid
interferon-independent expression of defense factors for short-term protection, whereas
mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed
kinetics, amplifying and stabilizing the antiviral response.
In addition to PRRs, which inhibit viral infections indirectly by activating signaling cascades
that result in the transcription of IFN and other antiviral molecules, there are intrinsic antiviral
factors which act blocking viral replication immediately and directly, often before the onset of
IFN response, like PKR, MxA, TRIM5α or the IFIT and IFITM families [16]. Intrinsic innate
factors preexist in certain cell types though they can be further induced by IFNs to amplify
their antiviral activity.
Recent work supports the non-redundant functional requirement for TLRs and RLRs [17]. On
the contrary, the cooperation and crosstalk between different PRRs mediates activation of an
effective immune response and host defense against viral infections [8, 18]. Unique links
between NLRs and RLRs signaling responses have also been identified [10, 19]. Polymicrobial
infection involve complex host interactions that are likely to engage a variety of response
pathways including different PRRs.
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IFNs exert auto- and paracrine actions within a few hours in response to a viral infection. Their
protective effect is dual: they induce an antiviral cellular state and promote the clearance of
infected cells in synergy with other proapoptotic agents as tumor necrosis factor (TNF).
Through the secretion of IFN, triggered by activation and translocation to the nucleus of NF-
κB, IRF3 and IRF7, the antiviral response can be amplified and spread to surrounding
uninfected cells by binding to the IFN-α/β receptor (IFNAR) in the cell surface. Binding of the
cytokine triggers a Jak-STAT signaling pathway and subsequently activates hundreds of IFN-
stimulated genes (ISGs), most of them encoding proteins with antiviral functions such as
inhibition of viral gene expression or degradation of the viral genome [20].
In addition to its antiviral properties, IFNs exhibit potent immunomodulatory properties that
contribute to their antiviral effect such as stimulation of the effector function of natural killer
(NK) cells, cytotoxic T lymphocytes and macrophages, upregulation of MHC class I and II
molecules, induction of immunoglobulin production by B cells and stimulation of proliferation
of memory T cells [21]. This enables several ways to control viral replication by modulating of
the innate and adaptive immune responses [22]. Type-I IFNs act through activation and
maturation of dendritic cells leading to MHC upregulation. They can also regulate certain
chemokines, chemokine receptors and costimulatory molecules, which, in turn, stimulate CD4-
and CD8-positive T cell responses and promote Th1 differentiation, modulating T lymphocyte
responses [23].
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Figure 2. Schematic representation of viral RNA detection by TLRs and RLRs and signalling pathways
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Induction of innate immune signaling pathways through PRRs is a crucial step antagonised
by many viruses [24, 25]. Over 170 different virus-encoded IFN antagonists from 93 different
viruses had been reported by 2010 (reviewed in [26]), and the list keeps constantly growing,
indicating that most viruses interfere with multiple stages of the IFN response. Four main
mechanisms are used to circumvent host innate responses: general inhibition of gene expres‐
sion, and sequestration, proteoltytic cleavage or proteasome degradation of key factors of the
IFN circuit such as RLRs, MAVS, IRFs, Jak/STAT, PKR... Several IFN antagonists are conserved
within different RNA virus families, while that seems not to be the case for DNA viruses [26].
This can be explained by the multi-functionality of RNA virus proteins, imposed by restriction
in genome size, unlike large dsDNA viruses which might have a higher coding capacity for
new viral proteins displaying a wider range of antagonistic activities.
The potential of IFN antagonists knockout viruses as promising candidates for live virus
vaccines has been suggested based on studies with Influenza A/B viruses, Japanese encepha‐
litis virus, human respiratory syncytial virus and coronaviruses [26-29]. These severely
attenuated viruses are rapidly cleared in vivo by a potent IFN response, while inducing long-
lasting immune memory due to their replication competent nature. Viral miRNAs may also
function in evasion of the host antiviral response (reviewed in [30]). The contribution to viral
evasion of type-I IFN response of small non-coding subgenomic flavivirus RNAs generated
as degradation products by a host exoribonuclease, has been recently shown [31]. Hence, IFN
antagonists are good targets for antiviral drugs development.
3. RNA motifs in the viral genome can trigger innate responses
Accurate discrimination of self from non-self is critical to avoid immune triggering against self
that leads to autoimmunity [32]. In that sense, it has been proposed for hepatitis C virus (HCV)
that a combinatorial non-self signature in the viral genome for PRR binding may lead to
accurate PAMP discrimination [33].
TLRs involved in recognition of the viral genomes are TLR3, TLR7/8 and TLR9, all of them
localized to the endosomal compartment [34]. TLR3 is widely expressed in innate immune
cells with the exception of neutrophils and pDCs and responds to dsRNA, a common viral
PAMP, and its synthetic analog polyriboinosinic-polyribocytidylic acid (poly I:C) [35]. TLR7
and TLR8 are closely related receptors that recognize nearly any long ssRNA with some
differences between them. Short ssRNA containing certain motifs preferentially activate TLR7,
and activation with synthetic agonists specific to TLR7 or TLR8 trigger different cytokine
profiles [36]. TLR9 is highly expressed in pDCs and responds to the unmethylated deoxycy‐
tidylate-phosphate-deoxyguanylate (CpG) motifs in viral and bacterial DNA [37].
Different features have been defined for RIG-I recognition as RNA PAMPs, including the
presence of a free 5´-triphosphate, absent from eukaryotic cytoplasm due to RNA metabolism
in the nucleus, length (longer than 19 nt), secondary structure characteristics (a base-pairing
region of 10-20 nt near the 5´-ppp) [38] and nucleotide sequence motifs (such as a 3´-poly
U/UC tract in the HCV genome) [33]. Panhandle structures adopted by Sendai virus DI-
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genomes or self-complementary influenza virus genome have been described as potent
PAMPs sensed by RIG-I [39]. Data on MDA5 ligands are scarce. MDA5 seems to sense dsRNA
analog poly I:C in mice [40] and higher-order RNA structures present in infected cells have
been found to activate MDA5 [41]. A recent report shows the direct interaction of MDA5 with
dsRNA replicative intermediate forms of positive strand RNA viruses [14]. RLRs have evolved
to sense the presence of largely different sets of viruses but not always acting in a mutually
exclusive way [13, 42].
In addition to the direct antiviral function of RNase L degrading ssRNA, RNase L can generate
viral or host-derived small RNAs that amplify the IFN response by generating PAMPs that
activate the RLR pathway. RNase L mediated cleavage of HCV RNA generates svRNA that
activates RIG-I, thus propagating innate immune signaling to the IFN-β gene [43, 44].
Given the ability of RLRs to sense viral RNAs and activate IFN signaling cascades that
eliminate viral infections, many viruses have developed immune evasion strategies to
overcome detection by RLRs. This is carried out through RNA modification of viral RNA
genomes to prevent host detection [24]. For example, some viruses engage cap snatching (e.g.
influenza virus), modification of 5´-ppp to monophosphate through virus encoded enzymes
(e.g. Borna disease virus, Lassa virus), 2´O-methylation of viral mRNA cap structure by virus
encoded methyltransferases, exploiting nucleotide modifications found at higher frequency
in eukaryotic versus prokaryotic/viral RNA, and the use of proteins to protect the 5´ends
(picornavirus have a virus encoded protein, VPg, covalently linked to the 5´end of their
genome) or overhangs (e.g. arenavirus) [24].
In 2008, Saito et al. showed that the 3´ non-coding region (NCR) of HCV (a flavivirus) encoded
PAMP motifs triggering innate immune signaling in the host cell. Thus, the 100 nt-polyuridine
motif (poly U/UC) within the 3´ NCR was identified as a potent PAMP, substrate of RIG-I
recognition and immune triggering in human and murine cells [45]. In contrast, the structured
3´-terminal X region failed to trigger signaling. The entire HCV 5´NCR, containing four major
stem-loop structures including the internal ribosome entry site (IRES), was a weak inducer of
IFN promoter signaling. However, prior treatment of cells with IFN-β to increase RIG-I levels
rendered them responsive to signaling induced by the 5´NCR or the X region [45], suggesting
that dsRNA regions of the HCV genome are not potent PAMPs but may confer signaling
during the IFN response. Some studies on the 5´- and 3´-NCRs of other flaviviruses show
remarkable differences in their IFN-inducing capacity. The 5´and 3´NCRs of dengue virus
(DEN) elicited low but measurable stimulation of innate immune signaling, while the smaller
highly structurally conserved 3´-terminal stem-loop RNAs of DEN, West Nile virus (WNV)
and yellow fever viruses were minimally active [46]. Additionally, the base-pairing extent of
the 5´-triphosphate of the RNAs may have an enhancing effect on RLR recognition and
signaling [38, 47]. Therefore, the ability of different RNAs as IFN inducers must be tested
independently, being difficult to predict their behaviour/potency by their sequence, secondary
structure or homology with analog molecules. In this sense, we have recently shown that
FMDV (a picornavirus) full-length transcripts with the 3´NCR deleted induce lower levels of
IFN-β than complete RNA transcripts in cell culture [48]. These results are equivalent to those
reported for HCV transcripts lacking the PAMP motif poly-U/UC. In this case, it has been
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proposed that, as the virus must maintain this motif in the 3´NCR for its viability, the host
takes advantage of this and targets this region as a discriminator of PAMP RNA through RIG-
I interaction [45]. Thus, HCV infection seems to be regulated by hepatic immune defenses
triggered by the cellular RIG-I helicase. For FMDV, we also found that RNA transcripts
corresponding to structural domains predicted to enclose stable dsRNA regions in the 5´and
3´NCRs of the viral genome were able to trigger an IFN-α/β response in epithelial porcine
kidney cultured cells and induce an antiviral state [48] (Figure 3). A direct link between
antiviral activity induced by FMDV NCR transcripts and IFN could be established in cultured
cells, as treatment with monoclonal antibodies against IFN-α/β effectively blocked the antiviral
activity induced by the RNAs [48]. Different levels of IFN-β mRNA induction were observed
for the different RNAs assayed, being the one mimicking the complete 3´NCR, enclosing two
predicted stem-loop structures, the best inducer. The in vitro RNA transcripts corresponding
to the complete 5´ NCR, the IRES and the S hairpin (Figure 3), were also able to induce IFN-
β transcription, though at lower levels than the 3´NCR transcript. The removal of the poly A
tail within the 3´NCR RNA had a detrimental effect on IFN-β induction, but milder than
removal of the 5´-ppp by treatment with alkaline phosphatase, which strongly reduced but
did not completely abolish induction. However, deletion of any of the 3´NCR stem-loop (SL)
structures rendered RNAs minimally active for IFN-β signaling, suggesting a relevant role for
RNA structure in this region for its recognition as a PAMP. Unlike the FMDV NCR transcripts,
the 5´-end of the viral genome is linked to the viral protein VPg lacking a 5´-ppp, making
difficult to draw conclusions on the putative role of these structural regions in viral patho‐
genesis.
Encouraged by the results of IFN-β induction in swine cultured cells transfected with the NCR
transcripts, we aimed to address the potential of such molecules as type-I IFN inducers in vivo.
For that, the FMDV NCRs were inoculated intraperitoneally into Swiss suckling mice and the
levels of IFN-α/β proteins and antiviral activity in sera were measured [48]. Newborn mice are
a suitable model for innate immune responses while their adaptive immunity is still immature.
All the FMDV NCRs were able to induce a peak of IFN-α/β in sera of the inoculated animals
at 8 h after injection, remarkably higher than those observed for poly I:C-transfected mice. This
peak was maintained up to 24 h in the case of the S RNA. The presence of antiviral activity in
sera from NCR-transfected mice was also detected and measured, and a good correlation with
IFN-α/β levels tested by ELISA was found. Interestingly, even those transcripts showing a
lower capacity for IFN-β induction in porcine cultured cells were able to induce an innate
immune response in mice. On one hand, this suggests that the effect of low level-inductions
of type-I IFN observed in cultured cells can be magnified in vivo. On the other hand, the action
of other viral sensors in vivo, mainly TLRs, may account for the enhancing effect observed.
Thus, the specific immunostimulatory activity of each NCR RNA may be different depending
on the host cell context assayed. This was the case for the IRES: despite of its complex structure,
it was a poor inducer in cultured cells. However, the IRES acted as a strong IFN inducer in
suckling mice. We further showed that the innate immune responses triggered by the NCRs
in suckling mice resulted in a reduced susceptibility to FMDV infection in all cases, being
remarkable the antiviral effect of inoculation with the IRES RNA [48, 49].
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The antiviral effect exerted in vivo by these small synthetic non-infectious RNA molecules was
analyzed extensively, using a wide range of viral doses and different serotype isolates [49]. The
time course of resistance to FMDV of the RNA-transfected mice was also studied. Inoculation
with all RNAs remarkably increased the 50% lethal dose (LD50) of the virus, determined for the
control group. Mice inoculated with IRES or S transcripts 24 h before challenge became at least
10000-fold less susceptible to the virus than PBS-inoculated mice. Interestingly, 90% of the IRES-
transfected mice survived after infection with a viral dose of 7 x 106 plaque forming units (PFU)
(undiluted viral stock), showing the outstanding protective effect of these RNA molecules. The
level of protection against viral infection was dose-dependent. Complete or very high protec‐
tion was achieved when IRES RNA was inoculated 8 or 24 h prior to FMDV infection with 7 x
104 PFU, with 100 and 86% survival, respectively. Inoculation of the transcripts at longer times
pre-infection strongly decreased their protective effect against viral infection. Co-inoculation of
S or IRES transcripts and the virus induced high levels of protection (about 90%), and the IRES
RNA had a higher protective effect inoculated at 8 h than at 4 h before infection, suggesting that
a fine balance between the routes activating the innate immune response by the RNAs and the
viral replication kinetics or antagonistic mechanisms triggered by the virus, might determine
either the outcome of disease or the viral clearance. Additionally, high survival percentages were
observed for those groups inoculated with the RNAs at short times after infection (89 and 87%
of mice inoculated with the IRES at 4 h and 8 h post-infection survived, respectively), and complete
protection (100% survival) was achieved when mice were inoculated with the S transcripts at 4
or 8 h post-infection [49]. No protective effect was observed for mice inoculated with the RNAs
24 h after viral infection. These results suggest that the antiviral response induced by the RNAs
is rapidly established and effective to counteract the viral replication if administered shortly
after infection, while 24 h later it was too late to restrain the progress of infection. Our data support
the potential use of this RNAs as both prophylactic as well as therapeutic molecules in a certain
time window. These small non-infectious RNAs could be useful to induce a rapid antiviral state
in combination with effective FMD vaccines to overcome the problem of the susceptibility
window until protective levels of antibodies are produced by vaccinated animals. These results
provide, as well, a new insight into broad-spectrum antiviral development strategies (Figure 3).
4. Exploiting innate responses for antiviral, therapeutic and adjuvation
strategies
The example described above illustrates the potential of RNA regions in the viral genome,
known to elicit innate responses, for antiviral and therapeutic applications.
Viral pattern recognition system may offer unique translational implications in medical
approaches, taking advantage of the innate immune function of PRRs to trigger cell autono‐
mous responses in tumour cells along with cytotoxic T-cell responses that target tumour cells.
Tumour cells are much more sensitive to cytotoxic effects after RLR ligation than are untrans‐
formed cells, allowing for tumour-specific effects despite systemic application of the ligands
in mouse models [50, 51]. The concept of using targeted application of PAMPs to mimic a
situation of viral infection for clinical application like immunotherapy is being extensively
explored [52]. In addition to being interesting targets for the immunotherapy of cancer, RLRs
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have been found to play a role in other disease conditions like type-I diabetes and other
autoimmune diseases like psoriasis or selective IgA-deficiency [53-55]. RLRs ligands have been
shown to have a therapeutic effect for autoimmune inflammatory disease of the central
nervous system in mice [56].
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Other than its role in driving innate immune defenses, IFN plays a major role in modulating
the adaptive immune response [57]. IFN is required to promote T cell survival and clonal
expansion after antigen presentation. IFN also induces the cytolytic activity of NK cells and
cytotoxic lymphocytes and promotes B cell differentiation and antibody production, as well
as expression of MHC class I molecules [58, 59]. The specific role of RLR signaling in regulating
IFN production and its regulation of the adaptive immune response is less clear and appears
to vary from virus to virus [60].
Luke et al. showed that the potency of a DNA vaccine against influenza virus could be
augmented by the incorporation of a RIG-I activating immunostimulatory RNA into the vector
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backbone [61]. Mice receiving the vaccine exhibited increased virus-specific serum antibody
response as compared to those receiving the DNA vaccine alone. These results suggest that
RLR signaling can enhance antibody development after vaccination by activation of innate
immunity and improved adaptive immune responses. However, in a previous study Koyama
et al. found a defect in antigen-specific B and T cell activation in MyD88-defficient mice, unlike
MAVS-deficient mice, suggesting that adaptive immune responses against influenza A virus
are governed by the TLR pathway [62]. On the contrary, MAVS-deficient mice infected with
WNV displayed uncontrolled inflammation including elevated systemic IFN, proinflamma‐
tory cytokine and chemokine levels, and enhanced humoral responses marked by complete
loss of virus neutralization activity with a failure to protect against WNV infection [63]. This
work defined an innate/adaptive immune interface mediated through MAVS-dependent RLR
signaling that regulates the quantity, quality and balance of the immune response to WNV.
Using MDA5-defficient mice, Anz et al. showed that the loss of T regulatory cell function on
infection with encephalomyocarditis virus (EMCV) is strictly dependent on RLR signaling [64].
In a different study, a normal and effective adaptive immune response against respiratory
syncytial virus (RSV) infection was reported in the absence of both MAVS and MyD88, RLR-
and TLR-adaptor molecules, respectively [65]. All together, the results suggest that, in the case
of flavivirus and picornavirus infections, RLR signaling is important in the control of the
quantity, quality and balance of the adaptive immune response, with specific and differential
mechanisms of regulation operating depending on the specific virus infections. The under‐
standing of the molecular features underlying these processes could offer new strategies for
immune and antiviral therapy targeting the RLR pathway for therapeutic control of the viral
infection and enhancement of the induced immune response.
The vaccine development field is evolving from traditional whole cell vaccines to more defined
and safer subunit vaccines. In the idea of exploiting the innate responses in vaccine adjuvant
design, a growing demand for the use of immunopotentiators in poorly immunogenic subunit
vaccines is arising with the development of a new generation of vaccine adjuvants. New
vaccine adjuvants are designed to improve the recruitment and activation of dendritic cells,
then enabling transition from the innate to adaptive immune system for priming of B- and T-
cell responses. Endogenous or therapeutically induced early type-I IFN responses may confer
protection until adaptive immunity is activated to an extent that the pathogen can be elimi‐
nated. In that context, PRRs come into sight as targets of new vaccine adjuvants beside their
role as sentinels in innate immunity.
Evidence is now emerging that many empiric vaccines and adjuvants inherently stimulate
PRRs, like the yellow fever vaccine 17D, one of the most effective vaccines available, shown
to activate multiple DC subsets through stimulation of several TLRs (including TLR-7, -8 and
-9) [66], highlighting the potential of vaccination strategies that use combinations of different
PRRs ligands to stimulate polyvalent immune responses.
The current vaccine adjuvants licensed for use in human vaccines are limited [67], but other
PRR agonists in clinical stages of development are emerging as potential vaccine adjuvant
candidates [68], such as the TLR3 and MDA5 agonist poly I:C, a promising mucosal adjuvant
for intranasal H5N1 influenza vaccination [69]. Clearly, TLR agonists are the most clinically
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advanced in adjuvant development, but require additional considerations, as variation in TLR
expression and influence of age in responsiveness or the risk of autoimmunity by induction
of excessive inflammatory responses [68]. Other TLR agonists currently in clinical trials of a
malaria vaccine are the TLR-9 agonists CpG oligodeoxynucleotides (ODNs).
In addition to recognition of viral ssRNA like that derived from HIV (Human immunodefi‐
ciency virus) or influrenza viruses, TLR7/8 can also be activated by certain synthetic agonists
such as the imidazoquinoline derivatives imiquimod and resiquimod (R-848), as well as the
guanine nucleotide analog loxoribine. TLR7/8 imidazoquinolines can activate appropriate
immune cells and modulate cellular and humoral immunity and have been found to be
excellent vaccine adjuvants [70]. Most TLR agonists induce antibody and Th1 responses,
although some can induce Th2 and possibly Th17 responses. Knowledge of the response
outcomes in terms of cytokines, chemokines and T-cell subtypes generated by activation of
combination of PRRs would help in the design of vaccine formulations including the appro‐
priate combination of adjuvants in the future that can contribute to develop new vaccines
against infectious diseases.
In the case of FMDV, many efforts are being invested on development of new vaccine formula‐
tions aimed to improve currently used vaccines [71]. Although FMD vaccines are available since
the early 1900s, the disease still affects millions of animals around the globe and remains the
main sanitary barrier to the commerce of animals and animal products. Among the limitations
of the currently available inactivated antigen vaccines are the short duration of immunity and
the lack of serotype-cross protection. Administration of this vaccine or an experimental vaccine
based on a replication-defective human adenovirus (Ad5) vector that delivers the FMDV capsid
and 3C proteins requires ~7 days to induce protective immunity in animals [72, 73]. New
approaches aimed to shorten this susceptibility window and induce a more robust and long-
lasting adaptive immune response are being developed, such as expression of type-I,-II and –
III IFNs with Ad5 vectors with good but differential results depending on the host species assayed
[74, 75]. Treatment with IFN has proved, so far, to be the best biotherapeutic approach tested
against FMDV. Recent data show that poly I:C stabilized with poly-L-lysine and carboxymeth‐
yl cellulose (poly ICLC), a TLR-3 and MDA5 agonist, is a potent stimulator of IFN and ISGs in
swine and at an adequate dose is sufficient to induce complete protection against FMD [77]. A
different study shows that the combined application of recombinant adenoviruses expressing
IFN-α or siRNA and other antiviral agents such as ribavirin may enhance their inhibitory effect
on FMDV [77]. Our own data, discussed above, support the use of the FMDV NCR RNAs,
mimicking structural domains in the viral genome acting as potent type-I IFN inducers, as
promising non-infectious and synthetic molecules in future antiviral and vaccine develop‐
ments against FMDV and likely other viral infections.
5. Conclusions
Understanding how the innate immune system senses the infection of different viruses with
a variety of genome structures and signals and the crosstalk between different PRRs will help
to understand the complex regulation of immunity to infection. The increasing knowledge on
Use of RNA Domains in the Viral Genome as Innate Immunity Inducers for Antiviral Strategies and Vaccine
Improvement
http://dx.doi.org/10.5772/56099
203
the nature of PAMPs and sensor specificity will surely contribute to the development of safer
and more effective vaccines for infectious diseases. PRR agonists arise as promising molecules
due to their synergistic effects on cytokine production and contributing to effective immune
responses. The success of rationally designed vaccine formulations in the near future will likely
correlate with the advances on understanding cell signalling mechanisms as well as PRR
adjuvanticity and response outcomes. Targeted immunomodulatory strategies will require
knowledge of the virus-specific aspects of the pathway. Viral proteins with IFN antagonistic
activity are potential drug targets for antiviral strategies. Moreover, small, synthetic and non-
infectious RNAs mimicking viral PAMPs can act as potent IFN inducers and exert an antiviral
effect in vivo, providing new insight into broad-spectrum antiviral development strategies.
Acronyms and abbreviations
Ad5 replication-defective human adenovirus vector
APC Antigen presenting cell
CARD Caspase activation and recruitment domain
CLR C-type lectin receptor
CpG Unmethylated deoxycytidylate-phosphate-deoxyguanylate
DC Dendritic cell
DEN Dengue virus
DI genomes Defective-interfering genomes
ds Double-stranded
EMCV Encephalomyocarditis virus
ER Endoplasmic reticulum
FMDV Foot-and-mouth disease virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
IFITM Interferon inducible transmembrane protein
IFN Interferon
IFNAR IFN-α/β receptor
IRES Internal ribosome entry site
IRF Interferon regulatory factor
ISG IFN-stimulated gene
JAK/STAT Janus kinase/signal transducers and activators of transcription
LD50 50% lethal dose
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LGP2 Laboratory of genetics and physiology-2
MAP Kinase Mitogen-activated protein kinase
MAVS Mitochondrial antiviral signaling
MDA5 Melanoma differentiation-associated gene 5
MHC Major histocompatibility complex
miRNA Micro RNA
NCR Non-coding region
NK Natural killer
NLR Nucleotide oligomerization domain (NOD-like receptor)
ODNs Oligodeoxynucleotides
ORF Open reading frame
PAMP Pathogen-associated molecular pattern
pDC Plasmacytoid dendritic cell
PFU Plaque forming units
PKR Protein kinase R
Poly I:C Polyriboinosinic-polyribocytidylic acid
Poly ICLC poly-L-lysine and carboxymethyl cellulose
PRR Pattern-recognition receptor
RIG-I Retinoic acid-inducible gene-1
RLR RIG-I-like receptor
RSV Respiratory syncytial virus
siRNA Small interfering RNA
SL Stem-loop structure
ss Single-stranded
svRNA Small viral RNA
TIR Toll/Interleukin-1 receptor
TLR Toll-like receptor
TNF Tumor necrosis factor
TRIF TIR-domain-containing adaptor inducing interferon
TRIM Tripartite motif protein
VPg Virus encoded protein
WNV West Nile virus
Table 1. List of the acronyms and abbreviations used in this chapter
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